BACKGROUND: Previous studies have demonstrated that serological markers can assist in diagnosing inflammatory bowel disease (IBD). In this study, we aim to build a diagnostic tool incorporating serological markers, genetic variants, and markers of inflammation into a computational algorithm to examine patterns of combinations of markers to (1) identify patients with IBD and (2) differentiate patients with Crohn's disease (CD) from ulcerative colitis (UC). METHODS: In this cross-sectional study, patient blood samples from 572 CD, 328 UC, 437 non-IBD controls, and 183 healthy controls from academic and community centers were analyzed for 17 markers: 8 serological markers (ASCA-IgA, ASCA-IgG, ANCA, pANCA, OmpC, CBir1, A4-Fla2, and FlaX), 4 genetic markers (ATG16L1, NKX2-3, ECM1, and STAT3), and 5 inflammatory markers (CRP, SAA, ICAM-1, VCAM-1, and VEGF). A diagnostic Random Forest algorithm was constructed to classify IBD, CD, and UC. RESULTS: Receiver operating characteristic analysis compared the diagnostic accuracy of using a panel of serological markers only (ASCA-IgA, ASCA-IgG, ANCA, pANCA, OmpC, and CBir1) versus using a marker panel that in addition to the serological markers mentioned above also included gene variants, inflammatory markers, and 2 additional serological markers (A4-Fla2 and FlaX). The extended marker panel increased the IBD versus non-IBD discrimination area under the curve from 0.80 (95% confidence interval [CI], ±0.05) to 0.87 (95% CI, ±0.04; P < 0.001). The CD versus UC discrimination increased from 0.78 (95% CI, ±0.06) to 0.93 (95% CI, ±0.04; P < 0.001). CONCLUSIONS: Incorporating a combination of serological, genetic, and inflammation markers into a diagnostic algorithm improved the accuracy of identifying IBD and differentiating CD from UC versus using serological markers alone.
BACKGROUND: Previous studies have demonstrated that serological markers can assist in diagnosing inflammatory bowel disease (IBD). In this study, we aim to build a diagnostic tool incorporating serological markers, genetic variants, and markers of inflammation into a computational algorithm to examine patterns of combinations of markers to (1) identify patients with IBD and (2) differentiate patients with Crohn's disease (CD) from ulcerative colitis (UC). METHODS: In this cross-sectional study, patient blood samples from 572 CD, 328 UC, 437 non-IBD controls, and 183 healthy controls from academic and community centers were analyzed for 17 markers: 8 serological markers (ASCA-IgA, ASCA-IgG, ANCA, pANCA, OmpC, CBir1, A4-Fla2, and FlaX), 4 genetic markers (ATG16L1, NKX2-3, ECM1, and STAT3), and 5 inflammatory markers (CRP, SAA, ICAM-1, VCAM-1, and VEGF). A diagnostic Random Forest algorithm was constructed to classify IBD, CD, and UC. RESULTS: Receiver operating characteristic analysis compared the diagnostic accuracy of using a panel of serological markers only (ASCA-IgA, ASCA-IgG, ANCA, pANCA, OmpC, and CBir1) versus using a marker panel that in addition to the serological markers mentioned above also included gene variants, inflammatory markers, and 2 additional serological markers (A4-Fla2 and FlaX). The extended marker panel increased the IBD versus non-IBD discrimination area under the curve from 0.80 (95% confidence interval [CI], ±0.05) to 0.87 (95% CI, ±0.04; P < 0.001). The CD versus UC discrimination increased from 0.78 (95% CI, ±0.06) to 0.93 (95% CI, ±0.04; P < 0.001). CONCLUSIONS: Incorporating a combination of serological, genetic, and inflammation markers into a diagnostic algorithm improved the accuracy of identifying IBD and differentiating CD from UC versus using serological markers alone.
Authors: Nora Meggyesi; Lajos S Kiss; Magdalena Koszarska; Martin Bortlik; Dana Duricova; Laszlo Lakatos; Tamas Molnar; Martin Leniček; Libor Vítek; Istvan Altorjay; Maria Papp; Zsolt Tulassay; Pal Miheller; Janos Papp; Attila Tordai; Hajnalka Andrikovics; Milan Lukas; Peter Laszlo Lakatos Journal: World J Gastroenterol Date: 2010-11-07 Impact factor: 5.742
Authors: M C Cénit; A Alcina; A Márquez; J L Mendoza; M Díaz-Rubio; V de las Heras; G Izquierdo; R Arroyo; O Fernández; E G de la Concha; F Matesanz; E Urcelay Journal: Genes Immun Date: 2010-03-04 Impact factor: 2.676
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: Michael A McGuckin; Rajaraman Eri; Lisa A Simms; Timothy H J Florin; Graham Radford-Smith Journal: Inflamm Bowel Dis Date: 2009-01 Impact factor: 5.325
Authors: Stephen J O'Brien; Jacob Hallion; Katharina M Scheurlen; Casey Fiechter; James Burton; Mason Paas; Miranda Schmidt; Sarah Gardner; Maurice R Eichenberger; Jianmin Pan; Shesh Rai; Susan Galandiuk Journal: J Gastrointest Surg Date: 2021-01-14 Impact factor: 3.452
Authors: Moorthy Krishnan; Harrison M Penrose; Nilay N Shah; Ronald R Marchelletta; Declan F McCole Journal: Inflamm Bowel Dis Date: 2016-12 Impact factor: 5.325